what are the factors that contribute to the high survival rate for CML patients treated with imatinib?

 The high survival rates for chronic myeloid leukemia (CML) patients treated with imatinib can be attributed to several factors, including:

• Early diagnosis: Most people are diagnosed with CML through a blood test called a complete blood count (CBC) before they have any symptoms. A CBC counts the number of different kinds of cells in the blood. A CBC is often done as part of a regular medical checkup. People with CML have high levels of white blood cells
  1
  . Early diagnosis allows for early treatment, which can improve outcomes.
• Targeted therapy: Imatinib is a type of targeted therapy that works by blocking the action of an abnormal protein that causes CML cells to grow and divide. Imatinib is highly effective in treating CML, and most patients achieve a complete cytogenetic response with the standard dose of 400 mg/day of imatinib
  2
  .
• mproved response ratesI: More than 80% of newly diagnosed patients with CML in the chronic phase will achieve a complete cytogenetic response with the standard dose of 400 mg/day of imatinib. The probability of progression-free survival is strongly correlated with the level of response, approaching 100% in those patients who achieve molecular response
  2
  .
• Long-term follow-up: Studies have shown that patients who receive imatinib for CML have high rates of survival even after 10 years of treatment
  3
  4
  . Long-term follow-up is important to ensure that patients continue to receive appropriate care and treatment.
• Improved supportive care: As survival rates for CML have improved, so has supportive care for patients. This includes better management of side effects from treatment, such as nausea, fatigue, and muscle cramps, as well as psychological support for patients and their families
  5
  .

Overall, the combination of early diagnosis, targeted therapy, improved response rates, long-term follow-up, and improved supportive care has contributed to the high survival rates for CML patients treated with imatinib.